中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 1
Jan.  2023
Turn off MathJax
Article Contents

Treatment of primary biliary cholangitis by targeting intestinal flora

DOI: 10.3969/j.issn.1001-5256.2023.01.029
Research funding:

Health Science and Technology Project of Inner Mongolia (202201282);

Natural Science Foundation of the Inner Mongolia (2022LHMS08019)

More Information
  • Corresponding author: LIU Yanqi, 109307436@qq.com (ORCID: 0000-0002-4735-6712)
  • Received Date: 2022-05-10
  • Accepted Date: 2022-06-12
  • Published Date: 2023-01-20
  • Primary biliary cholangitis (PBC) is a progressive cholestatic liver disease targeting biliary epithelial cells, and the concept of "treating diseases by intervening with the gut" has become a research hotspot in recent years. In the future, probiotics may be used to improve the abundance and distribution of intestinal flora, reshape the intestinal microenvironment, and intervene against the progression of PBC. This article reviews the gut microbiota and the clinical application of probiotics, so as to provide ideas for finding new treatment strategies for PBC.

     

  • loading
  • [1]
    YOU H, MA X, EFE C, et al. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis[J]. Hepatol Int, 2022, 16(1): 1-23. DOI: 10.1007/s12072-021-10276-6.
    [2]
    GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 93-110. DOI: 10.1038/s41575-019-0226-7.
    [3]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary biliary cholangitis(2021)[J]. J Clin Hepatol, 2022, 38(1): 35-41. DOI: 10.3760/cma.j.cn112138-20211112-00794

    中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38(1): 35-41. DOI: 10.3760/cma.j.cn112138-20211112-00794
    [4]
    SHIMOYAMA S, KAWATA K, OHTA K, et al. Ursodeoxycholic acid impairs liver-infiltrating T-cell chemotaxis through IFN-γ and CX3CL1 production in primary biliary cholangitis[J]. Eur J Immunol, 2021, 51(6): 1519-1530. DOI: 10.1002/eji.202048589.
    [5]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update[J]. J Hepatol, 2021, 75(3): 659-689. DOI: 10.1016/j.jhep.2021.05.025.
    [6]
    ZENG Y, CHEN S, FU Y, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Viral Hepat, 2020, 27(2): 143-155. DOI: 10.1111/jvh.13216.
    [7]
    XIAO LY, XING AW, TAN SZ. Research advances in the association between liver failure and intestinal barrier injury[J]. J Clin Hepatol, 2021, 37(11): 2710-2714. DOI: 10.3969/j.issn.1001-5256.2021.11.049.

    肖玲燕, 邢阿雯, 谭善忠. 肝衰竭与肠道屏障损害关系的研究进展[J]. 临床肝胆病杂志, 2021, 37(11): 2710-2714. DOI: 10.3969/j.issn.1001-5256.2021.11.049.
    [8]
    GIORDANO DM, PINTO C, MARONI L, et al. Inflammation and the gut-liver axis in the pathophysiology of cholangiopathies[J]. Int J Mol Sci, 2018, 19(10): 3003. DOI: 10.3390/ijms19103003.
    [9]
    MA HD, ZHAO ZB, MA WT, et al. Gut microbiota translocation promotes autoimmune cholangitis[J]. J Autoimmun, 2018, 95: 47-57. DOI: 10.1016/j.jaut.2018.09.010.
    [10]
    LI Y, TANG R, LEUNG P, et al. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases[J]. Autoimmun Rev, 2017, 16(9): 885-896. DOI: 10.1016/j.autrev.2017.07.002.
    [11]
    GRAHAM JJ, MUKHERJEE S, YUKSEL M, et al. Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis[J]. Hepatology, 2022, 75(3): 518-530. DOI: 10.1002/hep.32193.
    [12]
    LI B, SELMI C, TANG R, et al. The microbiome and autoimmunity: a paradigm from the gut-liver axis[J]. Cell Mol Immunol, 2018, 15(6): 595-609. DOI: 10.1038/cmi.2018.7.
    [13]
    MORO-SIBILOT L, BLANC P, TAILLARDET M, et al. Mouse and human liver contain immunoglobulin a-secreting cells originating from peyer's patches and directed against intestinal antigens[J]. Gastroenterology, 2016, 151(2): 311-323. DOI: 10.1053/j.gastro.2016.04.014.
    [14]
    LLEO A, LEUNG P, HIRSCHFIELD GM, et al. The pathogenesis of primary biliary cholangitis: A comprehensive review[J]. Semin Liver Dis, 2020, 40(1): 34-48. DOI: 10.1055/s-0039-1697617.
    [15]
    YANG Y, CHOI J, CHEN Y, et al. E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants[J]. Hepatology, 2022, 75(2): 266-279. DOI: 10.1002/hep.32172.
    [16]
    TANAKA A, LEUNG P, GERSHWIN ME. Pathogen infections and primary biliary cholangitis[J]. Clin Exp Immunol, 2019, 195(1): 25-34. DOI: 10.1111/cei.13198.
    [17]
    BERTOLINI A, FIOROTTO R, STRAZZABOSCO M. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation[J]. Semin Immunopathol, 2022, 44(4): 547-564. DOI: 10.1007/s00281-022-00935-7.
    [18]
    MAYO MJ. Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?[J]. Hepatology, 2022, 76(2): 518-531. DOI: 10.1002/hep.32405.
    [19]
    XIANG J, ZHANG Z, XIE H, et al. Effect of different bile acids on the intestine through enterohepatic circulation based on FXR[J]. Gut Microbes, 2021, 13(1): 1949095. DOI: 10.1080/19490976.2021.1949095.
    [20]
    TANG R, WEI Y, LI Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67(3): 534-541. DOI: 10.1136/gutjnl-2016-313332.
    [21]
    SUN L, CAI J, GONZALEZ FJ. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5): 335-347. DOI: 10.1038/s41575-020-00404-2.
    [22]
    LI B, ZHANG J, CHEN Y, et al. Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary cholangitis[J]. Gut Microbes, 2021, 13(1): 1946366. DOI: 10.1080/19490976.2021.1946366.
    [23]
    CHEN W, WEI Y, XIONG A, et al. Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis[J]. Clin Rev Allergy Immunol, 2020, 58(1): 25-38. DOI: 10.1007/s12016-019-08731-2.
    [24]
    SEHGAL R, BEDI O, TREHANPATI N. Role of microbiota in pathogenesis and management of viral hepatitis[J]. Front Cell Infect Microbiol, 2020, 10: 341. DOI: 10.3389/fcimb.2020.00341.
    [25]
    MASLENNIKOV R, IVASHKIN V, EFREMOVA I, et al. Probiotics in hepatology: An update[J]. World J Hepatol, 2021, 13(9): 1154-1166. DOI: 10.4254/wjh.v13.i9.1154.
    [26]
    FOLEY MH, O'FLAHERTY S, ALLEN G, et al. Lactobacillus bile salt hydrolase substrate specificity governs bacterial fitness and host colonization[J]. Proc Natl Acad Sci U S A, 2021, 118(6): e2017709118. DOI: 10.1073/pnas.2017709118.
    [27]
    LIU Y, CHEN K, LI F, et al. Probiotic lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice[J]. Hepatology, 2020, 71(6): 2050-2066. DOI: 10.1002/hep.30975.
    [28]
    QI JC, XING WJ, DU Y, et al. Effect of ursodeoxycholic acid and microecological agents on intestinal flora in patients with primary biliary cholangitis[J]. J Pract Hepatol, 2020, 23(4): 524-527. DOI: 10.3969/j.issn.1672-5069.2020.04.018.

    齐敬聪, 邢文静, 杜洋, 等. 熊去氧胆酸联合微生态制剂治疗原发性胆汁性胆管炎患者对肠道菌群的影响[J]. 实用肝脏病杂志, 2020, 23(4): 524-527. DOI: 10.3969/j.issn.1672-5069.2020.04.018.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1788) PDF downloads(106) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return